<

SANOFI-AVENTIS (EPA:SAN) New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia

Transparency directive : regulatory news

11/06/2021 09:00



Other stories

28/03/2024 12:25
28/03/2024 16:58
28/03/2024 18:00
28/03/2024 21:54
28/03/2024 17:37
28/03/2024 18:06
28/03/2024 17:03
28/03/2024 14:01
28/03/2024 21:30
28/03/2024 13:48
28/03/2024 21:21
28/03/2024 14:54
28/03/2024 17:48
28/03/2024 18:38
28/03/2024 22:10
28/03/2024 20:51
28/03/2024 09:59
28/03/2024 18:03
27/03/2024 15:52
27/03/2024 19:23
28/03/2024 09:00
28/03/2024 22:21
28/03/2024 19:08
28/03/2024 21:31
28/03/2024 19:03
28/03/2024 17:25
28/03/2024 22:00
28/03/2024 19:55
28/03/2024 17:34
28/03/2024 20:41
27/03/2024 21:46
27/03/2024 15:13
28/03/2024 17:55
27/03/2024 13:40
28/03/2024 13:25
28/03/2024 12:57
28/03/2024 16:44
28/03/2024 02:42